| PP100511003938 |
Innopharmax Inc. |
INNO-D07001 |
gemcitabine; 2',2'-difluorodeoxycytidine |
Promoting .. |
Biliary tr.. |
Phase III, Phase II, Phase II |
View Details
|
| PP090713004008 |
Nualtis (since Jun 2025), IntelGenx Corp. |
Exordia, INT0007 |
tadalafil |
A PDE5 inh.. |
Erectile d.. |
NDA |
View Details
|
| PP120328009184 |
invIOs GmbH (since Jan 2022), An APEIRON Biologics AG |
APN401 |
autologous cell; Cbl-b/siRNA |
Targeting .. |
Pancreatic.. |
Phase I completed, Phase I completed |
View Details
|
| PP120328009186 |
invIOs GmbH (since Jan 2022), An APEIRON Biologics AG |
INV501, APN501 |
|
Immune sti.. |
Various ca.. |
Preclinical |
View Details
|
| PP120405009251 |
Ipsen Pharma(since Mar 2023), Albireo AB |
Bylvay, A4250 |
odevixibat |
A potent a.. |
Progressiv.. |
Approved, Phase III, Phase III |
View Details
|
| PP121129010518 |
Janssen Research & Development LLC, a J&J (since 2012), J&J PHARMACEUTICAL R&D, L.L.C., a J&J |
Sirturo, TMC207, R207910 |
bedaquiline |
An adenosi.. |
Tuberculos.. |
Approved, Phase III |
View Details
|
| PP130715011539 |
Astex Pharmaceuticals, Inc. |
Balversa, JNJ-42756493, JNJ-493 |
erdafitinib |
A Fibrobla.. |
Urogenital.. |
Approved, Phase III, Phase II |
View Details
|
| PP130804011701 |
Innate Pharma S.A. |
IPH2201, NN8765 |
monalizumab |
An anti-NK.. |
Non-small .. |
Phase III, Phase III, Phase I |
View Details
|
| PP130804011702 |
Innate Pharma S.A. |
IPH4102 |
lacutamab |
An anti-KI.. |
Cutaneous .. |
Phase II, Phase II, Phase II |
View Details
|
| PP140324012069 |
Nanobiotix |
NBTXR3, JNJ-1900 |
hafnium oxide, HfO2 crystals. |
A free rad.. |
Head and n.. |
Phase III, Phase II, Phase III completed, Phase II completed |
View Details
|